CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms

Inclusion criteria

• ✓. The subject or their legally authorized representative has provided written informed consent and is willing and able to comply with scheduled visits, study treatment, laboratory tests, and other study procedures.
• ✓. Diagnosis of relapsed or refractory plasma cell neoplasms, defined as follows:
• ✓. Clonal plasma cells positive for BCMA and/or CD70 expression as determined by flow cytometry or immunohistochemistry;
• ✓. Patients with multiple myeloma, plasmacytoma, or plasma cell leukemia who have received at least three prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), and an anti-CD38 monoclonal antibody, and whose best response was less than partial response (PR) or who experienced disease progression after achieving at least PR;
• ✓. Patients with systemic light chain amyloidosis who have received at least two prior lines of therapy, including an anti-CD38 monoclonal antibody and either a proteasome inhibitor (PI) or an immunomodulatory agent (IMiD), and whose best response was less than partial response (PR) or who experienced disease progression after achieving at least PR.
• ✓. Aged 18 to 75 years (inclusive), male or female.
• ✓. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
• ✓. Life expectancy greater than 3 months from the date of informed consent.